Observations placeholder
Pergolide Mesylate
Identifier
019839
Type of Spiritual Experience
Background
It was withdrawn in 2007 but it appears it is still being prescribed
A description of the experience
Pergolide (trade name Permax) is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease.
Parkinson's disease is associated with low levels of the neurotransmitter dopamine in the brain. Pergolide has some of the same effects as dopamine in the body.
In 2007 pergolide was withdrawn from the U.S. market for human use after several published studies revealed a link between the drug and increased rates of valvular heart disease.
On Jan, 14, 2016: 320 people reported to have side effects when taking Pergolide mesylate. Among them, 18 people (5.62%) have Hallucination.
Time on Pergolide mesylate when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 0.00% | 85.71% | 0.00% | 0.00% | 14.29% | 0.00% | 0.00% |
On Jan, 28, 2016: 320 people reported to have side effects when taking Pergolide mesylate. Among them, 5 people (1.56%) have Death.
Time on Pergolide mesylate when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
Gender of people who have Death when taking Pergolide mesylate :
Female | Male | |
Death | 16.67% | 83.33% |
Age of people who have Death when taking Pergolide mesylate :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Death | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
Top conditions involved for these people :
- Myocardial infarction (2 people, 40.00%)